Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vincent Tapia

Physician Assistant Casa Grande, AZ Physician Assistant

NPI 1255560710 CMS profile 102056

1637 E Monument Plaza Cir, Casa Grande, AZ 85222

Open in the dashboard

General payments

$4,778

288 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Tapia of Casa Grande, AZ is reported in the CMS Open Payments database as having received $4,778 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $650 32
2024 General $928 41
2023 General $1,212 72
2022 General $1,037 76
2021 General $952 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Tapia
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Vincent Tapia were reported at $650. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Vincent Tapia Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $952 $132 $37–$438 $132
2022 $1,037 $155 $48–$522 $149
2023 $1,212 $167 $52–$557 $160
2024 $928 $178 $55–$600 $164
2025 $650 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $631 60 payments
  2. AstraZeneca Pharmaceuticals LP $501 17 payments
  3. Novo Nordisk Inc $453 37 payments
  4. Amgen Inc. $274 16 payments
  5. Otsuka America Pharmaceutical, Inc. $225 10 payments
  6. Lilly USA, LLC $221 13 payments
  7. GlaxoSmithKline, LLC. $203 12 payments
  8. Abbott Laboratories $180 11 payments
  9. Teva Pharmaceuticals USA, Inc. $151 8 payments
  10. Sunovion Pharmaceuticals Inc. $146 8 payments
  11. Other $1,792 96 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,760 287 payments
  2. Entertainment $18 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $368 23 payments
  2. FARXIGA $360 7 payments
  3. Ozempic $320 28 payments
  4. BREZTRI $311 4 payments
  5. GEMTESA $285 13 payments
  6. RYBELSUS $269 23 payments
  7. REXULTI $225 10 payments
  8. YUPELRI $184 10 payments
  9. AIRSUPRA $168 3 payments
  10. Repatha $153 9 payments
  11. Other $3,422 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

5,272

Median for Physician Assistant: 241

Drug cost

$445,490

Median for Physician Assistant: $4,110

Branded share of claims

24.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 57 $79,730
Eliquis Apixaban Brand 47 $50,395
Xarelto Rivaroxaban Brand 48 $44,370
Vraylar Cariprazine Hcl Brand 26 $43,197
Jardiance Empagliflozin Brand 34 $29,681
Myrbetriq Mirabegron Brand 32 $22,087
Gemtesa Vibegron Brand 35 $21,185
Farxiga Dapagliflozin Propanediol Brand 36 $18,421
Januvia Sitagliptin Phosphate Brand 12 $18,416
Mounjaro Tirzepatide Brand 13 $13,584

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $137
$137 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $89
$89 — —
VRAYLAR
  • AbbVie, Inc. $87
$87 26 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $79
$79 36 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record